Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

Abstract Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up p...

Full description

Bibliographic Details
Main Authors: Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu, Yuhua Li
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Biomarker Research
Subjects:
Chimeric antigen receptor
CAR T cell therapy
Acute lymphocytic leukemia (ALL)
Positive relapse
Mechanism
Strategy
Online Access:http://link.springer.com/article/10.1186/s40364-020-00197-1

Internet

http://link.springer.com/article/10.1186/s40364-020-00197-1

Similar Items